Abstract
Everolimus, like sirolimus, appears to allow for calcineurin inhibitor minimization, which may allow less nephrotoxicity without compromising efficacy. It appears to protect against CMV infection, and the potential antitumor and antiproliferative activity in in-stent neointimal growth may have significant clinical benefits.
| Original language | English |
|---|---|
| Pages (from-to) | 323-326 |
| Number of pages | 4 |
| Journal | Current Opinion in Organ Transplantation |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2003 |
| Externally published | Yes |
Keywords
- Certican
- Everolimus
- Immunosuppression
- SDZ RAD
- TOR inhibitors